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Abstract
Juvenile myelomonocytic leukemia (JMML), an overlap of myelodysplastic / myeloprolifera-
tive neoplasm, is an intractable pediatric myeloid neoplasm. Epigenetic regulation of tran-
scription, particularly by CpGmethylation, plays an important role in tumor progression,
mainly by repressing tumor-suppressor genes. To clarify the clinical importance of aberrant
DNAmethylation, we studied the hypermethylation status of 16 target genes in the genomes
of 92 patients with JMML by bisulfite conversion and the pryosequencing technique. Among
16 candidate genes,BMP4,CALCA,CDKN2A, and RARB exhibited significant hypermethy-
lation in 72% (67/92) of patients. Based on the number of hypermethylated genes, patients
were stratified into three cohorts based on an aberrant methylation score (AMS) of 0, 1–2, or
3–4. In the AMS 0 cohort, the 5-year overall survival (OS) and transplantation-free survival
(TFS) were good (69% and 76%, respectively). In the AMS 1–2 cohort, the 5-year OS was
comparable to that in the AMS 0 cohort (68%), whereas TFS was poor (6%). In the AMS 3–4
cohort, 5-year OS and TFS were markedly low (8% and 0%, respectively). Epigenetic analy-
sis provides helpful information for clinicians to select treatment strategies for patients with
JMML. For patients with AMS 3–4 in whom hematopoietic stem cell transplantation does not
improve the prognosis, alternative therapies, including DNAmethyltransferase inhibitors and
newmolecular-targeting agents, should be established as treatment options.
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Introduction
Juvenile myelomonocytic leukemia (JMML) is an aggressive myeloid neoplasm of early child-
hood characterized by the excessive proliferation of myelomonocytic cells and hypersensitivity
to granulocyte-macrophage colony-stimulating factor [1]. JMML is categorized as an overlap
of myelodysplastic syndrome and myeloproliferative neoplasm by the World Health Organiza-
tion classification [2]. Mutations in PTPN11, NF1, NRAS, KRAS, or CBL, which induce deregu-
lation of the RAS signaling pathway, are responsible for the pathogenesis of up to 80% of cases
of JMML [3–5]. Recently, we identified secondary somatic mutations in SETBP1 and JAK3 in
patients with JMML that were associated with poor prognosis [6–8]. The clinical management
of patients with JMML according to the genetic status is of great interest because of the possible
prognostic variety in JMML; however, this idea remains controversial [9–10].
Methylation of cytosines in promoter CpG dinucleotides is an important negative regulator
of gene expression in the human genome. Aberrant methylation of CpG islands in the pro-
moter regions of tumor-suppressor genes plays a fundamental role in the pathogenesis of vari-
ous cancers [11,12], including myeloid malignancies [13,14]. Several studies have described
aberrant DNAmethylation in JMML [15,16], but most researchers studied small cohorts,
excluding a report of 127 cases of JMML by the EuropeanWorking Group of MDS
(EWOG-MDS) showing that aberrant DNAmethylation of four genes (BMP4, CALCA,
CDKN2B, and RARB) is associated with poor prognosis [17]. However, no report has con-
firmed this observation because JMML is extremely rare. In this study, to further clarify the
clinical importance of aberrant DNA methylation in JMML, we quantitatively evaluated the
DNAmethylation pattern in the promoter regions of 16 selected genes using pyrosequencing
of genomic DNA from bone marrow specimens at diagnosis from 92 patients with JMML.
Materials and Methods
Patients
We studied 92 children (61 males and 31 females) with JMML or Noonan syndrome-associated
myeloproliferative disorder (NS-MPD) who were diagnosed in various institutions throughout
Japan. The diagnosis of JMML was based on internationally accepted criteria [2]. Written
informed consent was obtained from each patient’s parents before sample collection. This
study was approved by the Ethics Committees of Nagoya University Graduate School of Medi-
cine. The clinical records of patients were obtained from each institution. The detailed patient
characteristics were described in our previous report7 and are summarized in Table 1. With
genetic analysis, mutations in PTPN11, NF1, NRAS, KRAS, and CBL were found in 39 (42%),
7 (8%), 12 (13%), 13 (14%), and 11 (12%) patients, respectively. In addition, 16 patients had
SETBP1 or JAK3mutations [7].
Laboratory methods
We examined genomic DNA derived from bone marrow specimens at the diagnosis of JMML
or NS-MPD. As normal controls, age- and tissue-matched samples were obtained from 16
healthy donors. Genomic DNA was extracted from the peripheral blood of normal controls
and bone marrow specimens of children with JMML using a QIAamp DNA Blood Mini kit
(QIAGEN, Hilden, Germany) and a QIAamp DNA Investigator kit (QIAGEN), according to
the manufacturer’s instructions. The DNA was bisulfite-modified using an EpiTect Bisulfite kit
(QIAGEN). We quantified CpG methylation in the promoter regions of 16 candidate genes
(APC, BMP4, CALCA, CDH13, CDKN2A, CDKN2B, CHFR, DAPK1, ESR1, H19, IGF2AS,
MGMT,MLH1, RARB, RASSF1, and TP73), which were reported to be highly methylated in
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JMML [15–17], or other hematological malignancies [18–25]. Bisulfite-converted DNA was
amplified using a PyroMark PCR kit (QIAGEN) with specific primers for the CpG islands of
target genes [26]. The informations of the region of each target genes investigated were listed
in S1 File. To calculate the DNA methylation level of each targeted CpG, the peak heights in
the resulting pyrogram describe the ratio of cytosine to thymine at each analyzed CpG site,
which reflects the proportion of methylated DNA, and the average methylation of the all CpG
sites for each gene was calculated [27]. We defined aberrant hypermethylation as higher than
three standard deviations above the mean of the methylation level in normal controls.
Table 1. Patient characteristics.
Total cohort (n = 92) AMS 0 (n = 25) AMS 1–2 (n = 54) AMS 3–4 (n = 13)
Gender (Male/Female) 61/31 13/12 39/15 9/4
Median age at diagnosis, months (range) 16 (1–160) 8 (1–59) 23 (1–160) 29 (1–74)
Diagnosis (JMML/NS-MPD) 85/7 20/5 52/2 13/0
Hypermethylated genes, n
BMP4 41 0 29 12
CALCA 32 0 20 12
CDKN2A 32 0 20 12
RARB 13 0 9 4
Genetic mutations in the RAS pathway, n
PTPN11 39 6 26 7
NF1 9 1 5 3
RAS (NRAS/KRAS) 28 (15/13) 8 (5/3) 18 (9/9) 2 (1/1)
CBL 14 7 3 3
No mutation 10 4 5 1
Secondary genetic mutations, n
SETBP1 and JAK3 1 0 1 0
SETBP1 only 6 0 5 1
JAK3 only 9 0 5 4
No secondary mutation 76 25 43 8
Metaphase cytogenetics at diagnosis, n
Normal karyotype 76 24 41 11
Monosomy 7 8 1 7 0
Trisomy 8 4 0 3 1
Other abnormalities 4 0 3 1
WBC at diagnosis, ×109/L, median (range) 30.0 (1.0–563) 26.9 (1.0–131) 29.7 (5.6–113) 43.1 (15.3–563)
Mon at diagnosis, ×109/L, median (range) 4.6 (0.2–31.6) 4.5 (0.2–18.4) 4.5 (0.5–20.8) 5.8 (1.1–31.6)
HbF at diagnosis, %, median (range) 21 (0–68) 8 (0–68) 22 (0–63) 24 (8–56)
PLT at diagnosis, ×109/L, median (range) 61.0 (1.4–483) 112 (5.0–373) 53.0 (1.4–483) 49.0 (8–132)
HSCT (Yes/No) 56/36 6/19 43/11 7/6
Probability of 5-year TFS, % (95% CI) 15 (6–27) 69 (45–84) 6 (1–17) 0
Survival outcome (Alive/Dead) 62/30 20/5 41/13 1/12
Probability of 5-year OS, % (95% CI) 60 (46–71) 76 (45–91) 68 (50–81) 8 (0–29)
Abbreviations: AMS, aberrant methylation score; CI, confidential interval; HbF, hemoglobin F; HSCT, hematopoietic stem cell transplantation; JMML,
juvenile myelomonocytic leukemia; Mon, monocytes; NS-MPD, Noonan syndrome-associated myeloproliferative disorder; OS, overall survival; PLT,
platelet count; TFS, transplantation-free survival; WBC, white blood cell count.
doi:10.1371/journal.pone.0145394.t001
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Statistical analyses
Comparisons of proportions were performed using the χ2 test for heterogeneity or Fisher’s
exact test as appropriate. Mean ranks were compared with the Wilcoxon two-sample test. All
candidate predictive factors were investigated for their impact on the duration of transplanta-
tion-free survival (TFS), which was defined as the interval from diagnosis to hematopoietic
stem cell transplantation (HSCT) or death of any cause, and overall survival (OS), which was
defined as the time from diagnosis to death regardless of disease status using the Kaplan–Meier
estimate. The observation time of patients who had not progressed and who were alive at the
last follow-up visit was considered to be censored. Covariates with a p-value<0.10 in univari-
ate analyses were included in multivariate analyses. As estimates of the prognostic effect, haz-
ard ratios (HR) with 95% confidential intervals (CI) were calculated with Cox proportional
hazard models. All reported p-values were two-sided and the significance level was set at 0.05.
Statistical analyses were performed using Stata 12.0 (Stata Corporation, College Station, TX,
USA).
Results
Among 16 candidate genes, aberrant hypermethylation of BMP4 (41/92, 45%), CALCA (32/92,
35%), CDKN2A (32/92, 35%), CDKN2B (4/92, 4%), H19 (5/92, 5%), and RARB (13/92, 14%)
was detected in our cohort (Fig 1A). For the other 10 genes, no hypermethylation exceeding
the limit of detection was observed. Hypermethylation of BMP4, CALCA, CDKN2A, and RARB
in particular, resulted in a poorer outcome as indicated by the Kaplan–Meier estimates for TFS,
for which the probabilities of TFS for patients with and without methylation were: 31% and 0%
Fig 1. Summary of DNAmethylation in candidate genes. (A) The dot plot represents the frequencies of methylated CpG sites for each candidate gene in
the 92 patients with juvenile myelomonocytic leukemia. Aberrant hypermethylation was defined as >3 standard deviations above the mean methylation level
of the healthy control population. The threshold values of each gene are shown as red broken lines. (B) Kaplan–Meier plots of the patient groups, defined by
aberrant methylation of the indicated genes, are shown for BMP4, CALCA, CDKN2A, CDKN2B, H19, and RARB.
doi:10.1371/journal.pone.0145394.g001
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(p<0.001), for BMP4; 25% and 4% (p = 0.07), for CALCA; 25% and 0% (p<0.001), for
CDKN2A; and 22% and 0% (p = 0.04), for RARB, respectively (Fig 1B).
Thus, we considered that four of the candidate genes were aberrantly hypermethylated
(BMP4, CALCA, CDKN2B, and RARB) and assigned an aberrant methylation score (AMS; one
point for each methylated gene for these four genes) to further assess the genetic and clinical
impact of the hypermethylation. Accordingly, 25 (27%), 30 (33%), 24 (26%), 12 (13%), and one
(1%) patient had AMSs of 0, 1, 2, 3, and 4, respectively. Among the 7 patients with NS-MPD,
three and four had AMSs of 0 and 1, respectively, however, none of the patients had AMS of
2 or more. The AMSs in the cohort of 92 patients with JMML are summarized in Fig 2A. Of
the 16 patients with mutations in SETBP1 and/or JAK3, 0 (0%), 7 (44%), 4 (25%), 4 (25%), and
one (6%) patient had AMSs of 0, 1, 2, 3, and 4, respectively. However, of the other 76 patients
without mutations in SETBP1 or JAK3, 25 (33%), 23 (30%), 20 (26%), 8 (11%), and 0 (0%)
patients had AMSs of 0, 1, 2, 3, and 4, respectively. As shown in Fig 2B, the AMS of patients
with SETBP1 and/or JAK3mutations was significantly higher than that in patients without
these secondary mutations (p = 0.03).
The patients were classified into three cohorts according to the AMS score (Table 1 and Fig
3). The AMS 0 cohort displayed better survival without HSCT; specifically, the probabilities of
5-year TFS and OS in this cohort were 69% (95% CI, 45%–84%) and 76% (95% CI, 45%–91%),
respectively. Patients in the AMS 1–2 cohort were rescued by HSCT. The probabilities of
5-year TFS and OS in this cohort were 6% (95% CI, 1%–17%) and 68% (95% CI, 50%–81%),
respectively. In sharp contrast, the prognosis of patients in the AMS 3–4 cohort was not
improved by HSCT, as the probabilities of 5-year TFS and OS in this cohort were 0% and 8%
(95% CI, 0%–29%), respectively. Indeed, six of seven patients who received allogeneic HSCT in
the AMS 3–4 cohort died during observation. Their causes of death consisted of progressive
disease (n = 3), veno-occlusive disease (n = 2), and respiratory distress (n = 1), as shown in
Table 2.
According to multivariate analysis using the Cox proportional hazard model for covariates
including AMS (Table 3), an AMS of 1–4 (HR, 4.1; 95% CI, 1.5–11; p = 0.006), mutations in
PTPN11 or NF1 (HR, 3.5; 95% CI, 1.6–7.5; p = 0.002), and chromosomal aberrations (HR, 2.3;
95% CI, 1.1–4.7; p = 0.021) were independent predictors of poor TFS. Moreover, an AMS of
3–4 (HR, 4.4; 95% CI, 1.7–11; p = 0.002), chromosomal aberrations (HR, 4.1; 95% CI, 1.6–11;
p = 0.004), and platelet counts of less than 33 × 109/L (HR, 3.1; 95% CI, 1.4–7.3; p = 0.007)
were independent predictors of poor OS. On the contrary, in multivariate analysis for covari-
ates excluding AMS (Table 3), mutations in PTPN11 or NF1 (HR, 2.1; 95% CI, 1.2–5.1;
p = 0.01), chromosomal aberrations (HR, 3.7; 95% CI, 1.9–7.1; p<0.001), and platelet counts
of less than 33 x 109/L (HR, 2.0; 95% CI, 1.1–3.5; p = 0.02) were independent predictors of poor
TFS. Furthermore, chromosomal aberrations (HR, 3.8; 95% CI, 1.5–9.8; p = 0.006) and platelet
counts of less than 33 × 109/L (HR, 2.8; 95% CI, 1.2–6.2; p = 0.015) were independent predic-
tors of poor OS. Comparing these analyses, the AMS refined the predictability of outcomes
(S1 Fig).
Discussion
Negative regulation by aberrant methylation of the CpG islands of tumor-suppressor genes
accounts for the pathogenesis of malignancy [11,12]. In this study, we analyzed JMML cells
from 92 children to measure the CpG methylation of 16 candidate genes by bisulfite conversion
and pyrosequencing techniques. Aberrant methylation of six genes (BMP4, CALCA, CDKN2A,
CDKN2B, H19, and RARB) was detected in 4%–45% of our cohort. Four of these genes (BMP4,
CALCA, CDKN2B, and RARB) were consistent with those identified in the EWOG-MDS
Aberrant DNAMethylation in Children with JMML
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report, which described that CpG hypermethylation of these four genes was significantly asso-
ciated with poor prognosis in JMML. Of note, the method for measuring methylation in the
current study was different from that used in the EWOG-MDS study [17], suggesting that both
methods can analyze targeted CpG methylation, supporting the reasonability of both studies.
In our study, aberrant methylation of four genes (BMP4, CALCA, CDKN2A, and RARB)
was associated with poor prognosis. In contrast, EWOG-MDS study incorporated CDKN2B in
Fig 2. Profile of genetic mutations and aberrant methylation. (A) Mutation status of RAS pathway genes
and secondary genes (SETBP1 and JAK3) identified as gene targets. Aberrant methylation scores (AMS) in a
cohort of 92 patients with juvenile myelomonocytic leukemia are summarized. A rhombus denotes a patient
with Noonan syndrome-associated myeloproliferative disorder. (B) Mutations in SETBP1 and JAK3were
associated with a higher AMS. The mean AMS of patients with SETBP1 and/or JAK3mutations was higher
than that of patients without secondary mutations (p = 0.03).
doi:10.1371/journal.pone.0145394.g002
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the methylated gene sets, while CDKN2A was not included. In the current study, patients with
an aberrant methylation of CDKN2B tended to show a poorer outcome (p = 0.11); however, in
the current cohort, the size of the population with aberrant CDKN2B was small (4 of 92) com-
pared with the population size (28 of 127) observed in the EWOG study. This difference may
reflect the use of different methodologies in the two studies (pyrosequencing in the present
study and MassARRAY in the EWOG study). CDKN2A, also known as p16, is coded in 9p21,
and binds to CDK4, inhibiting the ability of CDK4 to interact with cyclin D and stimulate pas-
sage through the G1 phase of the cell cycle [28]. The role of CDKN2A in leukemogenesis is well
investigated. The first report in 1994 demonstrated that both alleles of p16 were completely or
partially deleted in human leukemia cells derived from patients [29]. Hemizygous deletions
and rearrangements of 9p21 are reported as among the most frequent cytogenetic abnormali-
ties detected in pediatric acute lymphoblastic leukemia [30]. A genome-wide analysis
Fig 3. Hypermethylation status and clinical outcome in patients with juvenile myelomonocytic leukemia (JMML). (A) Kaplan–Meier curves represent
the probability of transplantation-free survival (TFS) in the 92 patients with JMML. TFS was defined as the probability of being alive and transplantation free.
Both death and transplantation were considered events. The probability of 5-year TFS in the aberrant methylation score (AMS) 0 cohort (solid line) was
significantly higher than that in the AMS 1–2 (long dashed line) and AMS 3–4 cohorts (dashed line), p < 0.001. (B) Kaplan–Meier curves represent the
probability of overall survival (OS) in the 92 patients with JMML. Death was considered an event. The probability of OS in both the AMS 0 (solid line) and 1–2
cohorts (long dashed line) was significantly higher than that in the AMS 3–4 cohort (dashed line), p < 0.001.
doi:10.1371/journal.pone.0145394.g003























2 67 / M 3 PTPN11 − 46,XY − − 4 Dead Disease
progression
4 3 / F 3 CBL − 46,XX MSD
BMT
− 57 Alive -
6 74 / F 3 NF1 - 46,XX − − 10 Dead Disease
progression
7 52 / M 3 PTPN11 - 46,XY − − 17 Dead Disease
progression
17 41 / M 3 PTPN11 SETBP1 47,XY,+8 UR CBT − 6 Dead Disease
progression
19 1 / F 3 - - 46,XX − − 4 Dead Disease
progression
21 29 / M 3 PTPN11 JAK3 45,XY, del(6)
(q?),-20
UR CBT − 4 Dead VOD
41 3 / M 3 PTPN11 - 46,XY − − 1 Dead Respiratory
distress
43 11 / F 3 CBL - 46,XX − − 0 Dead Pulmonary
bleeding
45 43 / M 4 PTPN11 JAK3 46,XY UR
BMT
UR CBT 6 Dead VOD
48 23 / M 3 NF1 JAK3 46,XY MMRD
BMT
− 5 Dead Disease
progression
49 65 / M 3 PTPN11 JAK3 46,XY UR CBT UR BMT 14 Dead Disease
progression
53 9 / M 3 KRAS - 46,XY UR
BMT
− 7 Dead Respiratory
distress
Abbreviations: AMS, aberrant methylation score; BMT, bone marrow transplantation; CBT, cord blood transplantation; F, female; HSCT, hematopoietic
stem cell transplantation; M, male; MMRD, mismatched related donor; MSD, matched sibling donor; UR, unrelated; VOD, veno-occlusive disease.
doi:10.1371/journal.pone.0145394.t002
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demonstrated that a common variation at 9p21.3 (intron 1 of CDKN2A) influences the risk of
childhood acute lymphoblastic leukemia [31].
The current study indicated that aberrant methylation of multiple genes is a common phe-
nomenon in JMML; specifically, 73% of patients exhibited methylation of at least one of four
genes (BMP4, CALCA, CDKN2A, and RARB), whereas 40% of all patients had two or more
genes methylated. These observations suggest that the patient cohort of JMML includes a CpG
island methylator phenotype [17,32]. Moreover, methylation of multiple genes was signifi-
cantly associated with mutations in SETBP1 or JAK3, which were involved in the progression
rather than initiation of JMML [7]. Both aberrant methylation and secondary genetic muta-
tions are associated with poor clinical outcomes, reflecting the aggressive disease at diagnosis
of JMML. Indeed, our analyses identified that aberrant methylation is one of the independent
poor prognosis factors for outcomes and refined the predictability of outcomes. The prognosis
of patients with hypermethylation in three or all four genes was not improved by HSCT, as the
most frequent cause of death in these patients was progression of JMML despite HSCT.
The most exciting finding in the current study was that patients with JMML could be classi-
fied using the AMS. The AMS 0 cohort exhibited significantly better TFS than the AMS 1–2
and 3–4 cohorts. At the same time, the AMS 0 and 1–2 cohorts displayed significantly better
OS than the AMS 3–4 cohort. These results suggest that allogeneic HSCT improves the survival
of patients with an AMS of 1–2 but not 3–4, providing new insight into clinical decision-mak-
ing for patients with JMML. First, patients without aberrant methylation may survive without
allogeneic HSCT, indicating that for careful observation, a more specific prognostic marker
may need to be identified. Second, for patients with an AMS of 1–2, we provided evidence that
early HSCT may improve their outcomes. Finally, for patients with an AMS of 3–4 for whom
HSCT does not improve the prognosis, alternative therapies, including DNAmethyltransferase
inhibitors and new molecular-targeting agents, should be established as treatment options.
Epigenetic analysis provides helpful information for clinicians to select treatment strategies
for patients with JMML. Our findings unmasked a new aspect of the molecular pathogenesis of
JMML, which could facilitate the development of novel therapies; however, the study had some
limitations. We assessed methylation using materials obtained only at diagnosis but not at later
time points. In addition, our assessments were done for only 16 selected genes, whereas
genome-wide profiling was not performed. Moreover, our analyses were possibly influenced by
race bias. As JMML is an extremely rare disease, an international prospective study with risk
classification by genetic and epigenetic analysis is warranted.
Table 3. Multivariate model for transplantation-free and overall survival.






HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value
Mutation in PTPN11 or NF1 2.5 (1.2–5.1) 0.01 2.1 (0.6–7.1) 0.24 3.5 (1.6–7.5) 0.002 2.1 (0.6–7.7) 0.24
Chromosomal aberration 3.7 (1.–7.1) <0.001 3.8 (1.5–9.8) 0.006 2.3 (1.1–4.7) 0.021 4.1 (1.6–11) 0.004
Age at diagnosis >48 months 1.0 (0.5–1.8) 0.94 2.2 (0.9–5.2) 0.09 0.7 (0.4–1.4) 0.35 1.8 (0.7–4.5) 0.2
HbF >15% 1.7 (0.8–3.7) 0.15 1.9 (0.5–7.4) 0.33 1.0 (0.4–2.2) 0.92 1.2 (0.3–5.2) 0.79
PLT <33 × 109/L 2.0 (1.1–3.5) 0.02 2.8 (1.2–6.2) 0.015 1.6 (0.9–3.0) 0.1 3.1 (1.4–7.3) 0.007
Aberrant methylation score 1 – – – – 4.1 (1.5–11) 0.006 4.4 (1.7–11) 0.002
Abbreviations: CI, confidence interval; HbF, hemoglobin F; HR, hazard ratio; PLT, platelets.
doi:10.1371/journal.pone.0145394.t003
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Supporting Information
S1 Fig. Kaplan–Meier curves for transplantation-free and overall survival stratified by risk
groups based on a multivariate survival model. Patients were divided into three groups based
on a multivariate analysis model lacking the aberrant methylation score (AMS), i.e., the pres-
ence of a PTPN11 or NF1 mutation, chromosomal aberration, and low platelet count
(<33 × 109/L). We defined patients as having low (Low; without any covariates), intermediate
(Int; with 1 covariate), and high risk (High; with2 covariates). When we incorporated AMS
in the patient stratification, patients were divided into three groups based on a multivariate
analysis model including AMS (AMS model), i.e., the presence of a PTPN11 or NF1 mutation,
chromosomal aberration, low platelet count (<33 × 109/L), and high AMS (AMS1 for TFS).
We defined patients as having low (Low-M; without any covariates), intermediate (Int-M; with
1 covariates), and high risk (High-M; with3 covariates) using the AMS model. Kaplan–
Meier curves represent the probabilities of TFS based on the two models (panels A, B).
(TIFF)
S1 File. Summary of targeted CpGs in candidate genes. Primers for targeted CpGs in each
gene, excluding RARB, were supplied by commercial companies. Thus, the primers for APC
(product code #ASY516), BMP4 (#ADS1490), CALCA (#ADS1489), CDH13 (#ADS1461),
CDKN2B (#ADS708), CHFR (#ADS1462), DAPK1 (#ADS040), ESR1 (#ADS076), H19
(#ADS596), IGF2 (#ADS1051), and RASSF1 (#ASY574) were supplied by EPIGENDX (Hop-
kinton, MA, USA), while those for TP73 (#ADS658), CDKN2A (#972012), MGMT (#972032),
and MLH1 (#972022) were supplied by QIAGEN. PCR primers and the sequencing primer for
the CpGs of RARB were as reported by Shaw et al. The sequence informations of targeted
CpGs in candidate genes were summarized as bellow.
(PDF)
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